Skip to main content
NCBI home page
BMC Chemistry logoLink to BMC Chemistry
. 2025 Jul 8;19(1):204. doi: 10.1186/s13065-025-01557-4

Synthesis, reactions, antitumor and antimicrobial activity of new 5,6-dihydropyrrolo[2,1-a]isoquinoline chalcones

Mohamed A Mohamed Teleb 1, Monica G Kamel 1, Madonna S Mikhail 1, Hamdi M Hassaneen 1,✉, Ayman W Erian 1,✉, Mirna T Helmy 1
PMCID: PMC12239273  PMID: 40629449

Abstract

Stirring of 2-(6,7-dimethoxy-3,4-dihydroisoquinolin-1-yl)acetonitrile 1 with thiophene-2-carbaldehyde 2 in absolute ethanol in the presence of hydrochloric acid yielded 2-(6,7-dimethoxy-3,4-dihydroisoquinolin-1-yl)-3-(thiophen-2-yl)acrylonitrile hydrochloride 3. Refluxing of arylidene 3 with α-ketohydrazonoyl halides 4–7 in the presence of triethylamine in chloroform afforded dihydropyrrolo[2,1-a]isoquinolines 11–14. Claisen–Schmidt condensation of 11 with aryl aldehydes 15a-f or pyrazole aldehydes 17a-d in ethanol in the presence of sodium hydroxide solution produced chalcones 16a-f and 18a-d. Refluxing of chalcone 16f with hydrazine hydrate in ethanol afforded pyrazoline 19 which gave N-phenylcarbothioamide derivative 20 on stirring with phenyl isothiocyanate in dry ether. Also, refluxing of 19 with acetic anhydride or formic acid afforded acetyl-pyrazoline derivative 21 or formyl-pyrazoline derivative 22, respectively. Antitumor activity for some new synthesized compounds showed that compounds 16b and 16d had anticancer activities. Antimicrobial activities for the newly synthesized compounds revealed the most potent compounds 16c, 18b and 18d against E. coli, compounds 16b, 18b and 18d against B. mycoides, and compounds 16b, 16c and 18b against C. albicans. Moreover, compound 18b had the lowest MIC values against E. coli and B. mycoides, with MIC values of 40 and 60 µg/ml, respectively.

Supplementary Information

The online version contains supplementary material available at 10.1186/s13065-025-01557-4.

Keywords: Chalcones, Dihydroisoquinoline, Hydrazonoyl halides, Claisen–Schmidt condensation, Antitumor and antimicrobial activity

Introduction

The term of chalcone was created by the two authors, Stanislaw Kostanecki and Joseph Tambor [1]. Chalcones are exist in some naturally occurring substances from the flavonoids family. There are several conjugated compositions for chalcones, that known as 1,3-diphenylprop-2-en-1-one, in which the keto-ethylenic system (an α,β-unsaturated carbonyl ketone, -CO-CH═CH-) linked the two aromatic rings [2, 3]. They can exist with either the more stable trans-form or the less stable cis-form. Moreover, chalcones are the major ingredient of a wide variety of natural goods, including fruits, vegetables, teas, and other plants that are highly valued for their biological activities [4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17]. The most common methods for synthesizing chalcones via Suzuki reaction among phenyl boronic acid and cinnamoyl chloride or between phenyl vinyl boronic acid and benzoyl chloride [18], Heck reaction by coupling an aryl vinyl ketone with an aryl halide [19], Sonogashira coupling of the electron-insufficient group [20, 21], Miscellaneous reaction by coupling of phenylacetylene with benzaldehyde [22], Aldol reaction of ketones with benzaldehyde [23, 24]. Also, Claisen-Schmidt condensation for example via reaction between isoquinolines containing acetyl group and substituted aryl aldehydes [8, 25, 26, 27]. Chalcones exhibited a broad spectrum of biological activities such as antioxidant [4, 12, 28, 29, 30], analgesic [17], antiplatelet [16], anti-pyretic [31], antimalarial [15, 32], anti-inflammatory [11, 12, 13, 33], anticancer agents [4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 34, 35, 36], antifungal [10, 37] and antibacterial [5, 9, 38]. Also, heterocycles such as thiophenes [39], pyrazoles [40–41] and isoquinolines [42], are widely exist in pharmaceuticals and play an important role in medicinal chemistry. Besides, pyrrole exist in a number of pharmaceutical products and new active agents with a variety of pharmacological effects like: Aloracetam for treatment of Alzheimer disease, and Tolmetin anti-inflammatory (Fig. 1) [43, 44]. Moreover, fused heterocycles such as pyrroloisoquinoline and isoindoloisoquinolinone are present in pharmacologically active alkaloids like Nuevamine, Trolline, Oleracein E as well as Crispine A [45]. The indolo[2,1-a]isoquinolines are the principal structural moieties of Cryptaustoline and Cryptowoline alkaloids which exhibit strong anticancer activity and affinity for estrogen receptors. (Fig. 1) [46]. In continuation of our related work [8, 47, 48, 49, 50, 51], our goal of the present work is the synthesis of novel chalcones bearing pyrrolo[2,1-a]isoquinoline moiety and investigating their biological activity in vitro as anticancer agents against two human cancer cell lines: MCF7 (human Caucasian breast adenocarcinoma) and A549 (lung carcinoma), and antimicrobial activities for the newly synthesized compounds against E. coli, B. mycoides, and C. albicans.

Fig. 1.

Fig. 1

Open in a new tab

Pharmacologically active compounds

Results and discussion

Stirring of a mixture of 2-(6,7-dimethoxy-3,4-dihydroisoquinolin-1-yl)acetonitrile 1 [52, 53] with thiophene-2-carbaldehyde 2 in absolute ethanol in the presence of concentrated hydrochloric acid at room temperature yielded 2-(6,7-dimethoxy-3,4-dihydroisoquinolin-1-yl)-3-(thiophen-2-yl)acrylonitrile hydrochloride 3via Knoevenagel condensation (Scheme 1).

Scheme 1.

Scheme 1

Open in a new tab

Synthesis of arylidene 3

Reaction of arylidene 3 with α-ketohydrazonoyl halides 4–7 [54, 55, 56, 57] in refluxing chloroform using triethylamine as a catalyst afforded 3-acetyl or 3-aroyl-8,9-dimethoxy-2-(thiophen-2-yl)-5,6-dihydropyrrolo[2,1-a]isoquinoline-1-carbonitriles 11–14 (Scheme 2).

Scheme 2.

Scheme 2

Open in a new tab

Synthesis of 3-acetyl or 3-aroyl-8,9-dimethoxy-2-(thiophen-2-yl)-5,6-dihydropyrrolo[2,1-a]isoquinoline-1-carbonitriles 11–14

According to the suggested mechanism, nitrilimines 8, produced in situ by reaction of α-ketohydrazonoyl halides 4–7 with triethylamine in chloroform, reacted with arylidene 3 to give the intermediate 9 which underwent in situ 1,5-electrocyclization then lost phenyldiazene molecule to yield products 11–14. The skeletons of the products 11–14 were confirmed by their elemental analyses and spectral data (1H NMR and 13C NMR). The 1H NMR spectrum of compound 11, as example, revealed five singlet signals at δ 2.12, 3.94, 3.95, 6.78 and 7.80 corresponding to acetyl group, two OCH3 groups, two protons at C7 and C10 of isoquinoline, respectively. In additions, three multiplet signals at δ 3.01–3.05, 4.59–4.63 and 7.14–7.50 corresponding to two CH2 groups at C5 and C6 of isoquinoline and three thienyl protons, respectively. Also, 21 signals for the asymmetric carbons appeared in its 13C NMR spectrum.

Claisen–Schmidt condensation of 3-acetyl-8,9-dimethoxy-2-(thiophen-2-yl)-5,6-dihydropyrrolo[2,1-a]isoquinoline-1-carbonitrile 11 with equimolar amounts of aryl aldehydes 15a-f or pyrazolyl aldehydes 17a-d [58] in ethanol in the presence of sodium hydroxide solution yielded the corresponding chalcones 16a-f and 18a-d, respectively (Scheme 3 and 4). The constitutions of these chalcones were confirmed from their spectral data and elemental analyses. The 1H NMR spectrum of chalcone 16f, as example, revealed five singlet signals at δ 2.35, 3.96, 3.98, 6.80 and 7.86 corresponding to protons of CH3 group, protons of two OCH3 groups and two protons at C7 and C10 of isoquinoline, respectively, three multiplet signals at δ 3.06–3.10, 4.63–4.67, 7.11–7.51 corresponding to protons of two CH2 group at C5 and C6 of isoquinoline and seven aromatic protons, respectively. Also, it showed two doublet signals corresponding to the two vinyl protons at δ 6.66 and 7.57 with coupling constant J = 15.6 Hz which confirms the trans configuration of the two vinyl protons. The structure was also confirmed by 13C NMR which revealed 27 signals for distinct carbon atoms.

Scheme 3.

Scheme 3

Open in a new tab

Synthesis of pyrrolyl chalcones 16a-f

The chalcone 16f was reacted with hydrazine hydrate in boiling ethanol to afford 8,9-dimethoxy-2-(thiophen-2-yl)-3-(5-(p-tolyl)-4,5-dihydro-1H-pyrazol-3-yl)-5,6-dihydropyrrolo[2,-1-a]isoquinoline-1-carbonitrile 19 which gave 3-(1-cyano-8,9-dimethoxy-2-(thiophen-2-yl)-5,6-dihydropyrrolo[2,1-a]isoquinolin-3-yl)-N-phenyl-5-(p-tolyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide 20 on stirring with phenyl isothiocyante in dry ether (Scheme 5).

Scheme 4.

Scheme 4

Open in a new tab

Synthesis of pyrazolyl chalcones 18a-d

Scheme 5.

Scheme 5

Open in a new tab

Synthesis of pyrazoline derivatives 19 and 20

Moreover, 3-(1-acetyl-5-(p-tolyl)-4,5-dihydro-1H-pyrazol-3-yl)-8,9-dimethoxy-2-(thiophen-2-yl)-5,6-dihydropyrrolo[2,1-a]isoquinoline-1-carbonitrile 21 and 3-(1-formyl-5-(p-tolyl)-4,5-dihydro-1H-pyrazol-3-yl)-8,9-dimethoxy-2-(thiophen-2-yl)-5,6-dihydropyrrolo[2,1-a]isoquinoline-1-carbonitrile 22 were prepared via refluxing of pyrazoline derivative 19 with acetic anhydride or formic acid, respectively (Scheme 6). The structures of the isolated products were established by their spectral data and elemental analyses (see Experimental). The 1H NMR spectrum of compound 21, as example, showed six singlet signals at δ 2.31, 2.37, 3.96, 3.97, 6.80 and 7.81 corresponding to CH3 group, acetyl group, two OCH3 groups, two protons at C7 and C10 of isoquinoline, respectively, six multiplet signals at δ 2.64–2.72, 3.09–3.13, 3.26–3.35, 4.61–4.67, 5.32–5.35 and 7.01–7.38 corresponding to three protons of pyrazoline, two CH2 group at C5 and C6 of isoquinoline and seven aromatic protons. Also, 29 signals appeared in the 13C NMR spectrum for the distinct carbons.

Scheme 6.

Scheme 6

Open in a new tab

Synthesis of N-acetyl and N-formylpyrazoline derivative 21 and 22

Antitumor activity

MCF7 (breast cancer cell line isolated in 1970 from a 69-year-old Caucasian woman) and A549 (lung carcinoma) were obtained from the American type culture collection (ATCC). The cells were propagated in DMEM supplemented with 10% heat-inactivated FBS, 1% L-glutamine, HEPES buffer and 50 µg/mL gentamycin. All cells were maintained at 37 °C in humidified atmosphere with 5% CO2 and were subcultured two times a week. Cell toxicity was monitored by determining the effect of the test samples on cell morphology and cell viability. Cells were suspended in RPMI 1640 medium for MCF7 and in DMEM for A549, 1% antibiotic-antimycotic mixture (10,000 U/mL Potassium Penicillin, 10,000 µg/mL Streptomycin Sulfate and 25 µg/mL Amphotericin B) and 1% L-glutamine at 37 ºC under 5% CO2. The results showed that compounds 16b and 16d possess moderate antitumor activities in the range of 56.8–77.6% on MCF7 and A549 cell lines. Ther rest of the compounds showed low activity against MCF7 and A549 cell lines (Table 1).

Table 1.

In vitro antitumor activity of some newly synthesized Chalcones

Sample Code MCF7 [Human Caucasian breast adenocarcinoma] A549
[Lung carcinoma cell line]
IC50 IC50
16b 60.3 81.1
16c ---- ----
16d 62.7 82.2
18b ---- ----
18c ---- ----
18d ---- ----
Control (DMSO) 0 0
Negative control 0 0
Open in a new tab

Lethal concentration of the sample which causes the death of 50% of cells in 48 hrsIC90: Lethal concentration of the sample which causes the death of 90% of cells in 48 hrs

MTT assay

Yellow MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) was reduced to purple formazan in a mitochondrial dependent method to determine cell viability [59].

All of the following processes were carried out in a sterile environment utilizing a Laminar flow cabinet with a biosafety rating of II.

Cells were batches generated for 10 days before being seeded at a concentration of 10 × 103 cells/well in new complete medium for growth in 96-well microtiter plastic plates at 37 ºC for 24 h under 5% CO2 utilizing a water jacketed Carbon dioxide isolator. The media was extracted, a fresh medium (without serum) was inserted, and cells were cultured either alone (negative control) or with sample of various concentration to get the desired concentration of (100-50-25-12.5-6.25-3.125-0.78 and 1.56 ug/mL). After 48 h of the incubation process, aspirate the medium and add 40 ul of MTT salt (2.5 µg/mL) to each well. Incubate for another four hours at 37ºC with 5% CO2. To terminate the reaction and to dissolve the generated crystals, 200 µL of 10% SDS (Sodium dodecyl sulphate) in the presence of deionized water has been added for each well and left overnight at 37ºC. A positive control of 100 µg/mL was utilized as a recognized cytotoxic natural substance, resulting in 100% fatality within the identical conditions [60, 61].

The absorption was also determined with a microplate multi-well detector with 595 nm and a baseline wavelength at 620 nm. Statistical significance was determined among samples and negative controls (cells with vehicle) using the SPSS 11 program’s independent t-test. The percentage for change in viability was estimated using the following formula: ((Reading of extract/Reading of negative control) -1) x 100 (Fig. 2).

Fig. 2.

Fig. 2

Open in a new tab

In vitro cytotoxicity of tested compounds 16b and 16d at different concentration using MTT test

Antimicrobial activity

This study used three microbiological species: Escherichia coli for Gram-negative bacteria, Bacillus mycoides for Gram-positive bacteria, and Candida albicans for yeast. The examined microbial species evolved on nutrient agar (70148 Nutrient agar, Fluka, Spain) overnight at 37 °C and used for inoculation (Table 2).

Table 2.

Antimicrobial activity assessment of the new synthesized compounds using agar diffusion method

Compound Inhibition zones diameter (mm)
G− G+ Fungi
E. coli B. mycoides C. albicans
16a 10 ± 0.00 12 ± 0.00 11 ± 0.04
16b 11 ± 0.96 17 ± 0.33 16 ± 0.44
16c 18 ± 0.85 11 ± 0.48 16 ± 1.32
16d 11 ± 0.18 11 ± 0.83 10 ± 0.07
16e 10 ± 1.07 10 ± 0.22 11 ± 0.46
16f 12 ± 0.02 12 ± 0.14 10 ± 1.00
18a 11 ± 1.06 10 ± 0.00 11 ± 0.00
18b 18 ± 1.08 17 ± 0.18 16 ± 0.46
18c 11 ± 0.68 11 ± 0.65 12 ± 0.23
18d 18 ± 1.11 17 ± 1.00 10 ± 0.44
19 10 ± 0.05 12 ± 0.57 11 ± 0.08
20 12 ± 0.26 10 ± 0.00 10 ± 0.00
21 11 ± 0.15 11 ± 0.07 12 ± 0.23
22 10 ± 0.35 11 ± 0.71 11 ± 0.00

Gentamicin

(Antibacterial agent)

Amphotericin B

(Antifungal agent)

 11 ± 0.05 12 ± 0.33 15 ± 0.25
Open in a new tab

In the inoculated agar plates, 100 µL of dissolved chemicals (10 mg/mL) in DMSO were administered to 12 mm holes, and incubated overnight at 37 °C

To investigate the efficacy of the produced compounds as antimicrobial agents, 100 µL of resuspended overnight cultures at 37 °C (1 × 107 CFU/100 µL) were administered into the nutrient agar medium (70148 Nutrient agar, Fluka). The well diffusion experiment involved distributing the relevant compounds in wells (12 mm in diameter) perforated with a sterile cork borer in nutrient agar medium (70148 Nutrient agar, Fluka, Spain). 100 µL of each antiseptic solution (10 mg/mL) was inserted into each well. Gentamicin (10 mcg) was used as the positive control. Clear zone diameters were determined in millimeters following appropriate incubation (overnight at 37 °C) [47, 62].

Minimum inhibitory concentration (MIC) evaluation

The MIC values were determined using the broth dilution method [63, 64]. A stock solution (10.24 mg/mL) of each investigated compound in dimethyl sulfoxide (DMSO) was produced and subsequently diluted to 1024 µg/mL using Mueller-Hinton broth. In Mueller-Hinton medium, the strains were briefly utilized at 37 °C. After 5 h of bacterial development and growth, the culture became diluted to a concentration of 5 × 105 cells per milliliter. Bacterial solutions (150 µL) have been added to each well of a 96-well tissue culture plate with flat bottom. Two-fold series of dilutions were performed from the first to tenth wells, with final drug concentrations ranging from 1 to 512 µg/mL. Excess medium (150 µL) was removed from the final well. The plates were visually examined after being incubated at 37 °C for 24 h in an electro-heating standing temperature cultivator. The MIC of the sample with no turbidity was determined as the lowest concentration of a substance that totally inhibited bacterial growth. Each assay was done in triplicate (Table 3).

Table 3.

MIC of compounds 16b, 16c, 18b, 18d against the sensitive microorganism

Compound MIC (µg/ml)
G− G+ Fungi
E. coli B. mycoides C. albicans
16b ---- 125 420
16c 175 132 250
18b 40 60 600
18d 154 102 ----
Open in a new tab

Abbreviation: G− = Gram negative; G+ = gram positive; MIC = minimum inhibitory concentration

Structure–activity relationship

As shown in Fig. 3, the anticancer activity of the prepared chalcones 16 and 18 against MCF7 and A549 cancer cell lines increased when R = Cl and Br as shown in chalcones 16b and 16d as compared to the other chalcones. In addition, the presence of fluorine atom gave chalcone 16c the most potant activity against both E. coli and C. albicans. Also, chalcone 18b which contain a pyrazole moiety and chlorine atom has the most potant activity against E. coli, B. mycoides and C. albicans.

Fig. 3.

Fig. 3

Open in a new tab

Structure–activity relationship (SAR) study of the prepared chalcones 16 and 18

Conclusion

In summary, synthesis of novel dihydropyrrolo[2,1-a] isoquinoline chalcones was reported using Claisen–Schmidt condensation. We could manage to confirm the constitutions of these chalcones using different spectral data. The antitumor activity against two human cancer cell lines, namely, MCF7 (human Caucasian breast adenocarcinoma) and A549 (lung carcinoma) were evaluated. The results showed that compounds 16b and 16d possess antitumor activities. The antimicrobial activity of the newly synthesized compounds revealed the most potent compounds 16b, 16c, 18b and 18d. Moreover, compound 18b had the lowest MIC values.

Supplementary file.

The 1H and 13C NMR spectra of all new compounds are represented in the supplementary file.

“Experimental.

“The melting points were determined using an Electrothermal 9100 apparatus, and no corrections were applied. Infrared (IR) spectra were obtained with a Bruker Vector 22 FTIR spectrophotometer, utilizing KBr pellets. Nuclear Magnetic Resonance (NMR) spectra, including both ¹H and ¹³C, were recorded in CDCl₃ or DMSO-d₆ as solvents on a Varian Gemini NMR spectrometer operating at 300 MHz and 75 MHz, respectively, with tetramethylsilane (TMS) serving as the internal reference. Chemical shifts were expressed as δ values in parts per million (ppm). Mass spectrometry analysis was conducted using a Shimadzu GCMS-QP-1000 EX spectrometer under Electron Ionization (EI) at 70 eV. Elemental analyses were carried out at the Microanalytical Center of Cairo University. 2-(6,7-Dimethoxy-3,4-dihydroisoquinolin-1-yl)acetonitrile 1 [52, 53], hydrazonoyl halides 4–7 [54, 55, 56, 57], and pyrazole aldehydes 17 [58] were prepared according to reported procedures”.

Synthesis of 2-(6,7-dimethoxy-3,4-dihydroisoquinolin-1-yl)-3-(thiophen-2-yl)acrylonitrile hydrochloride(3).

To a mixture of 2-(6,7-dimethoxy-3,4-dihydroisoquinolin-1-yl)acetonitrile 1 (11.5 g, 50 mmol) and thiophene-2-carbaldehyde 2 (5.6 g, 50 mmol) in absolute ethanol (100 mL), concentrated hydrochloric acid (10 mL) was added at room temperature. The reaction mixture was stirred for 6 h. The formed precipitate was collected and crystallized from N,N-dimethylformamide to afford arylidene 3. Brown crystals; yield (78%); mp 209–211 ºC; IR (KBr) Inline graphic 2204 (CN) cm− 1; 1H NMR (300 MHz, DMSO–d6) δ 2.74–2.78 (m, 2 H, CH2), 3.81 (s, 3 H, OCH3), 3.82 (s, 3 H, OCH3), 3.87–3.95 (m, 2 H, CH2), 6.92–6.96 (m, 1H, Thienyl-H), 6.98 (s, 1H, Isoq-H), 7.16–8.14 (m, 4 H, Ar-H), 9.94 (s, 1H, N-HCl); 13C NMR (75 MHz, DMSO–d6) δ 26.4, 43.6, 55.9, 56.1, 99.1, 110.9, 114.3, 116.0, 122.0, 128.5, 129.0, 130.4, 134.7, 137.7, 147.0, 151.7, 152.2, 164.4; MS (EI, 70 eV) m/z (%): 360 (M+, 100). Anal. Calcd. For C18H17ClN2O2S (360.86): C, 59.91; H, 4.75; Cl, 9.82; N, 7.76; S, 8.88. Found: C, 59.80; H, 4.81; Cl, 9.90; N, 7.70; S, 8.95.

Synthesis of 8,9-dimethoxy-2-(thiophen-2-yl)-5,6-dihydropyrrolo[2,1-a]isoquinoline-1-carbonitrile derivatives (11–14).

To a mixture of 2-(6,7-dimethoxy-3,4-dihydroisoquinolin-1-yl)-3-(thiophen-2-yl)acrylonitrile hydrochloride 3 (0.72 g, 2 mmol) and α-ketohydrazonoyl halides 4–7 (2 mmol) in chloroform (20 mL), triethylamine (2 mL) was added at room temperature. The reaction mixture was refluxed for 6 h and then cooled, the excess chloroform was removed under reduced pressure and the residue was treated with ethanol (10 mL). The solid that precipitated was collected and crystallized from suitable solvent to give 11–14. The compounds prepared with their physical data are listed below:

3-Acetyl-8,9-dimethoxy-2-(thiophen-2-yl)-5,6-dihydropyrrolo[2,1-a]isoquinoline-1-carbonitrile (11):

Light brown crystals; CH3CN; yield (75%); mp 221–223 °C; IR (KBr) Inline graphic 2212 (CN), 1634 (CO) cm− 1; 1H NMR (300 MHz, CDCl3) δ 2.12 (s, 3 H, COCH3), 3.01–3.05 (m, 2 H, CH2), 3.94 (s, 3 H, OCH3), 3.95 (s, 3 H, OCH3), 4.59–4.63 (m, 2 H, CH2), 6.78 (s, 1H, Isoq-H), 7.14–7.50 (m, 3 H, Thienyl-H), 7.80 (s, 1H, Isoq-H); 13C NMR (75 MHz, CDCl3) δ 28.1, 29.8, 43.3, 55.9, 56.0, 91.5, 107.7, 110.5, 116.1, 117.6, 126.6, 127.5, 127.8, 128.8, 129.0, 129.2, 132.3, 139.0, 148.2, 150.3, 190.5; MS (EI, 70 eV) m/z (%): 378 (M+, 100). Anal. Calcd. For C21H18N2O2S (378.45): C, 66.65; H, 4.79; N, 7.40; S, 8.47. Found: C, 66.58; H, 4.71; N, 7.48; S, 8.37.

3-Benzoyl-8,9-dimethoxy-2-(thiophen-2-yl)-5,6-dihydropyrrolo[2,1-a]isoquinoline-1-carbonitrile (12):

Golden crystals; DMF + EtOH; yield (84%); mp 259–261 °C; 1H NMR (300 MHz, CDCl3) δ 3.07–3.12 (m, 2 H, CH2), 3.96 (s, 3 H, OCH3), 4.00 (s, 3 H, OCH3), 4.39–4.44 (m, 2 H, CH2), 6.76–7.38 (m, 7 H, Ar-H), 7.66 (d, 2 H, Ar-H, J = 9 Hz), 7.90 (s, 1H, Isoq-H); 13C NMR (75 MHz, CDCl3) δ 28.2, 43.1, 55.9, 56.1, 89.0, 107.6, 110.7, 116.7, 117.9, 126.2, 127.0, 127.1, 127.4, 127.8, 127.9, 128.6, 129.5, 132.2, 132.7, 137.6, 139.3, 148.3, 150.1, 187.2; MS (EI, 70 eV) m/z (%): 440 (M+, 100). Anal. Calcd. For C26H20N2O3S (440.52): C, 70.89; H, 4.58; N, 6.36; S, 7.28. Found: C, 70.95; H, 4.50; N, 6.30; S, 7.17.

8,9-Dimethoxy-2-(thiophen-2-yl)-3-(thiophene-2-carbonyl)-5,6-dihydropyrrolo[2,1-a]isoquinoline-1-carbonitrile (13):

Light brown crystals; DMF + EtOH; yield (83%); mp 264–266 ºC; 1H NMR (300 MHz, CDCl3) δ 3.06–3.11 (m, 2 H, CH2), 3.95 (s, 3 H, OCH3), 3.99 (s, 3 H, OCH3), 4.32–4.36 (m, 2 H, CH2), 6.79 (s, 1H, Isoq-H), 6.82–6.85 (m, 1H, Thienyl-H), 6.90–6.92 (m, 1H, Thienyl-H), 7.09 (d, 1H, Thienyl-H, J = 5.1 Hz), 7.20 (d, 1H, Thienyl-H, J = 5.1), 7.33 (d, 1H, Thienyl-H, J = 4.8), 7.54 (d, 1H, Thienyl-H, J = 4.8), 7.89 (s, 1H, Isoq-H); 13C NMR (75 MHz, CDCl3) δ 28.3, 43.1, 56.0, 56.1, 88.8, 107.6, 110.8, 116.8, 118.0, 126.0, 126.1, 127.1, 127.3, 127.7, 128.0, 132.8, 134.6, 134.7, 139.1, 144.1, 148.4, 150.2, 161.2, 178.9; MS (EI, 70 eV) m/z (%): 446 (M+, 100). Anal. Calcd. for C24H18N2O3S2 (446.54): C, 64.56; H, 4.06; N, 6.27; S, 14.36. Found: C, 64.67; H, 4.12; N, 6.20; S, 14.44.

3-(2-Naphthoyl)-8,9-dimethoxy-2-(thiophen-2-yl)-5,6-dihydropyrrolo[2,1-a]isoquinoline-1-carbonitrile (14):

Yellow crystals; CH3CN; yield (78%); mp 219–221 °C; 1H NMR (300 MHz, CDCl3) δ 3.08–3.12 (m, 2 H, CH2), 3.95 (s, 3 H, OCH3), 4.00 (s, 3 H, OCH3), 4.40–4.44 (m, 2 H, CH2), 6.60–6.63 (m, 1H, Ar-H), 6.81 (s, 1H, Isoq-H), 6.93–7.92 (m, 9 H, Ar-H), 8.17 (s, 1H, Isoq-H); 13C NMR (75 MHz, CDCl3) δ 28.2, 43.1, 55.9, 56.0, 88.9, 107.5, 110.7, 116.8, 117.9, 124.6, 126.1, 126.4, 126.9, 127.0, 127.3, 127.4, 127.9, 128.0, 128.3, 128.4, 129.2, 131.8, 131.9, 132.3, 134.8, 135.1, 139.3, 148.3, 150.1, 186.9; MS (EI, 70 eV) m/z (%): 490 (M+, 100). Anal. Calcd. for C30H22N2O3S (490.58): C, 73.45; H, 4.52; N, 5.71; S, 6.54. Found: C, 73.38; H, 4.60; N, 5.60; S, 6.47.

Synthesis of chalcone derivatives (16a-f) and (18a-d).

To a stirred mixture of 3-acetyl-8,9-dimethoxy-2-(thiophen-2-yl)-5,6-dihydropyrrolo[2,1-a]isoquinoline-1-carbonitrile 3 (1 mmol) and the appropriate aryl aldehydes 15a-f or pyrazole aldehydes 17a-d (1 mmol) in ethanol (30 mL), sodium hydroxide solution 20% (10 mL) was added, the reaction mixture was stirred for 6 h at room temperature, and left overnight. The resulting solid product that precipitated was filtered, washed with water and crystallized from a suitable solvent to give the corresponding chalcone derivatives 16a-f and 18a-d. The compounds prepared with their physical and chemical properties as follow:

3-Cinnamoyl-8,9-dimethoxy-2-(thiophen-2-yl)-5,6-dihydropyrrolo[2,1-a]isoquinoline-1-carbonitrile(16a):

White crystals; DMF + EtOH; yield (77%); mp 204–206 °C; IR (KBr) Inline graphic 2210 (CN), 1652 (CO) cm− 1; 1H NMR (300 MHz, CDCl3) δ 3.06–3.11 (m, 2 H, CH2), 3.96 (s, 3 H, OCH3), 3.98 (s, 3 H, OCH3), 4.64–4.68 (m, 2 H, CH2), 6.70 (d, 1H, CH, J = 15.6 Hz), 6.80 (s, 1H, Isoq-H), 7.16–7.53 (m, 8 H, Ar-H), 7.59 (d, 1H, CH, J = 15.6 Hz), 7.86 (s, 1H, Isoq-H); 13C NMR (75 MHz, CDCl3) δ 28.2, 43.3, 56.0, 56.1, 90.6, 107.8, 110.7, 116.4, 117.8, 125.3, 126.7, 127.7, 128.1, 128.2, 128.7, 129.6, 129.9, 130.2, 132.5, 134.7, 139.5, 141.8, 145.2, 148.4, 150.4, 181.8; MS (EI, 70 eV) m/z (%): 466 (M+, 100). Anal. Calcd. for C28H22N2O3S (466.56): C, 72.08; H, 4.75; N, 6.00; S, 6.87. Found: C, 72.16; H, 4.64; N, 6.09; S, 6.79.

3-(3-(4-Chlorophenyl)acryloyl)-8,9-dimethoxy-2-(thiophen-2-yl)-5,6-dihydropyrrolo[2,1-a]isoquinoline-1-carbonitrile (16b):

Yellow crystals; CH3CN; yield (82%); mp 227–229 °C; 1H NMR (300 MHz, CDCl3) δ 3.05–3.09 (m, 2 H, CH2), 3.95 (s, 3 H, OCH3), 3.97 (s, 3 H, OCH3), 4.63–4.67 (m, 2 H, CH2), 6.63 (d, 1H, CH, J = 15.9 Hz), 6.80 (s, 1H, Isoq-H), 7.09–7.56 (m, 8 H, Ar-H), 7.84 (s, 1H, Isoq-H); 13C NMR (75 MHz, CDCl3) δ 28.1, 43.2, 55.9, 56.0, 90.6, 107.6, 110.5, 116.2, 117.6, 125.7, 126.6, 127.6, 128.1, 128.2, 128.9, 129.1, 129.6, 132.3, 133.1, 135.9, 139.5, 140.0, 145.2, 148.2, 150.3, 181.2; MS (EI, 70 eV) m/z (%): 500 (M+, 100), 501 (M+, 30). Anal. Calcd. for C28H21ClN2O3S (501.00): C, 67.13; H, 4.23; Cl, 7.08; N, 5.59; S, 6.40. Found: C, 67.02; H, 4.30; Cl, 7.16; N, 5.67; S, 6.33.

3-(3-(4-Fluorophenyl)acryloyl)-8,9-dimethoxy-2-(thiophen-2-yl)-5,6-dihydropyrrolo[2,1-a]isoquinoline-1-carbonitrile (16c):

Orange crystals; DMF + EtOH; yield (84%); mp 220–222 °C; 1H NMR (300 MHz, CDCl3) δ 3.06–3.10 (m, 2 H, CH2), 3.96 (s, 3 H, OCH3), 3.98 (s, 3 H, OCH3), 4.63–4.68 (m, 2 H, CH2), 6.60 (d, 1H, CH, J = 15.6 Hz), 6.80 (s, 1H, Isoq-H), 6.96–7.59 (m, 8 H, Ar-H), 7.85 (s, 1H, Isoq-H); 13C NMR (75 MHz, CDCl3) δ 28.4, 43.1, 55.7, 56.2, 90.7, 107.6, 110.4, 116.2, 117.6, 124.6, 126.5, 127.6, 127.7, 127.8, 128.3, 129.5, 129.7, 130.0, 131.7, 132.3, 139.1, 140.6, 141.6, 148.1, 150.5, 181.6; MS (EI, 70 eV) m/z (%): 484 (M+, 100). Anal. Calcd. for C28H21FN2O3S (484.55): C, 69.41; H, 4.37; F, 3.92; N, 5.78: S, 6.62. Found: C, 69.34; H, 4.30; F, 3.81; N, 5.70; S, 6.55.

3-(3-(4-Bromophenyl)acryloyl)-8,9-dimethoxy-2-(thiophen-2-yl)-5,6-dihydropyrrolo[2,1-a]isoquinoline-1-carbonitrile (16d):

Orange crystals; DMF; yield (80%); mp 243–245 °C; 1H NMR (300 MHz, CDCl3) δ 3.05–3.10 (m, 2 H, CH2), 3.95 (s, 3 H, OCH3), 3.97 (s, 3 H, OCH3), 4.63–4.67 (m, 2 H, CH2), 6.65 (d, 1H, CH, J = 15.6 Hz), 6.80 (s, 1H, Isoq-H), 7.02 (d, 2 H, Ar-H, J = 8.1 Hz), 7.15–7.54 (m, 6 H, Ar-H), 7.85 (s, 1H, Isoq-H); 13C NMR (75 MHz, CDCl3) δ 28.4, 43.1, 55.9, 56.2, 90.8, 107.6, 110.8, 116.6, 117.6, 125.1, 126.8, 127.5, 128.3, 128.4, 128.6, 129.5, 129.9, 130.1, 132.7, 134.8, 139.4, 141.9, 145.4, 148.2, 150.6, 181.6; MS (EI, 70 eV) m/z (%): 544 (100), 545 (M+, 97). Anal. Calcd. for C28H21BrN2O3S (545.45): C, 61.66; H, 3.88; Br, 14.65; N, 5.14; S, 5.88. Found: C, 61.59; H, 3.80; Br, 14.53; N, 5.06; S, 5.81.

8,9-Dimethoxy-3-(3-(4-nitrophenyl)acryloyl)-2-(thiophen-2-yl)-5,6-dihydropyrrolo[2,1-a]isoquinoline-1-carbonitrile (16e):

Red crystals; CH3CN; yield (83%); mp 227–229 °C; 1H NMR (300 MHz, CDCl3) δ 3.08–3.12 (m, 2 H, CH2), 3.96 (s, 3 H, OCH3), 3.98 (s, 3 H, OCH3), 4.66–4.71 (m, 2 H, CH2), 6.76–6.81 (m, 2 H, Ar-H), 7.15–7.32 (m, 4 H, Ar-H), 7.57 (d, 2 H, Ar-H, J = 15.6 Hz), 7.86 (s, 1H, Isoq-H), 8.14 (d, 2 H, Ar-H, J = 8.7 Hz); 13C NMR (75 MHz, CDCl3) δ 28.2, 43.4, 55.7, 55.9, 90.4, 107.7, 110.7, 116.1, 117.4, 125.8, 126.4, 127.8, 128.2, 128.4, 128.8, 129.2, 129.8, 132.2, 133.3, 135.7, 139.4, 139.8, 145.4, 148.1, 150.1, 181.4; MS (EI, 70 eV) m/z (%): 511 (M+, 100). Anal. Calcd. For C28H21N3O5S (511.55): C, 65.74; H, 4.14; N, 8.21; S, 6.27. Found: C, 65.66; H, 4.26; N, 8.14; S, 6.20.

8,9-Dimethoxy-2-(thiophen-2-yl)-3-(3-(p-tolyl)-acryloyl)-5,6-dihydropyrrolo[2,1-a]isoquinoline-1-carbonitrile (16f):

Orange crystals; DMF + EtOH; yield (78%); mp 262–264 °C; 1H NMR (300 MHz, CDCl3) δ 2.35 (s, 3 H, CH3), 3.06–3.10 (m, 2 H, CH2), 3.96 (s, 3 H, OCH3), 3.98 (s, 3 H, OCH3), 4.63–4.67 (m, 2 H, CH2), 6.66 (d, 1H, CH, J = 15.6 Hz), 6.80 (s, 1H, Isoq-H), 7.11–7.51 (m, 7 H, Ar-H), 7.57 (d, 1H, CH, J = 15.6 Hz), 7.86 (s, 1H, Isoq-H); 13C NMR (75 MHz, CDCl3) δ 21.4, 28.2, 43.2, 55.9, 56.1, 90.5, 107.7, 110.6, 116.4, 117.8, 124.4, 126.6, 127.6, 127.8, 127.9, 128.1, 129.4, 129.5, 129.9, 131.9, 132.5, 139.3, 140.7, 141.8, 148.3, 150.3, 181.8; MS (EI, 70 eV) m/z (%): 480 (M+, 100). Anal. Calcd. for C29H24N2O3S (480.58): C, 72.48; H, 5.03; N, 5.83; S, 6.67. Found: C, 72.40; H, 5.15; N, 5.76; S, 6.74.

3-(3-(1,3-Diphenyl-1 H-pyrazol-4-yl)acryloyl)-8,9-dimethoxy-2-(thiophen-2-yl)-5,6-dihydropyrrolo[2,1-a]isoquinoline-1-carbonitrile (18a):

Yellow crystals; DMF + EtOH; yield (81%); mp 257–259 °C; 1H NMR (300 MHz, CDCl3) δ 3.17–3.19 (m, 2 H, CH2), 3.96 (s, 3 H, OCH3), 3.99 (s, 3 H, OCH3), 4.71–4.79 (m, 2 H, CH2), 6.65 (d, 1H, CH, J = 9 Hz), 6.72 (s, 1H, Isoq-H), 7.11 (d, 1H, CH, J = 9 Hz), 7.25–7.84 (m, 14 H, Ar-H), 7.97 (s, 1H, Isoq-H); 13C NMR (75 MHz, CDCl3) δ 28.4, 43.5, 56.0, 56.2, 90.3, 107.5, 110.8, 114.3, 116.5, 117.7, 117.9, 118.7, 124.6, 124.9, 126.4, 126.7, 126.9, 127.6, 127.8, 127.9, 129.6, 129.8, 129.9, 132.6, 133.2, 139.4, 139.5, 148.6, 150.4, 153.7, 156.4, 159.9, 181.6; MS (EI, 70 eV) m/z (%): 608 (M+, 100). Anal. Calcd. for C37H28N4O3S (608.72): C, 73.01; H, 4.64; N, 9.20; S, 5.27. Found: C, 73.10; H, 4.53; N, 9.27; S, 5.20.

3-(3-(3-(4-Chlorophenyl)-1-phenyl-1 H-pyrazol-4-yl)acryloyl)-8,9-dimethoxy-2-(thiophen-2-yl)-5,6-dihydropyrrolo[2,1-a]isoquinoline-1-carbonitrile (18b):

Yellow crystals; DMF; yield (82%); mp 262–264 °C; 1H NMR (300 MHz, CDCl3) δ 3.05–3.10 (m, 2 H, CH2), 3.95 (s, 3 H, OCH3), 3.98 (s, 3 H, OCH3), 4.64–4.68 (m, 2 H, CH2), 6.53 (d, 1H, CH, J = 15.6 Hz), 6.80 (s, 1H, Isoq-H), 7.22–7.70 (m, 14 H, Ar-H), 7.84 (s, 1H, Isoq-H); 13C NMR (75 MHz, CDCl3) δ 28.4, 43.1, 55.8, 56.4, 90.5, 107.8, 110.5, 116.3, 117.6, 118.3, 118.8, 124.9, 126.4, 126.5, 127.1, 127.4, 127.5, 127.8, 128.3, 129.1, 129.2, 129.3, 129.4, 129.7, 132.7, 133.0, 138.7, 139.3, 139.5, 148.2, 150.4, 153.4, 181.7; MS (EI, 70 eV) m/z (%): 642 (100), 643 (M+, 40). Anal. Calcd. for C37H27ClN4O3S (643.16): C, 69.10; H, 4.23; Cl, 5.51; N, 8.71; S, 4.98. Found: C, 69.18; H, 4.15; Cl, 5.43; N, 8.80; S, 4.86.

8,9-Dimethoxy-3-(3-(1-phenyl-3-(p-tolyl)-1 H-pyrazol-4-yl)acryloyl)-2-(thiophen-2-yl)-5,6-dihydropyrrolo[2,1-a]isoquinoline-1-carbonitrile (18c):

Orange crystals; DMF; yield (79%); mp 254–256 °C; 1H NMR (300 MHz, CDCl3) δ 2.42 (s, 3 H, CH3), 3.04–3.09 (m, 2 H, CH2), 3.95 (s, 3 H, OCH3), 3.98 (s, 3 H, OCH3), 4.62–4.67 (m, 2 H, CH2), 6.54 (d, 1H, CH, J = 15.6 Hz), 6.79 (s, 1H, Isoq-H), 7.22–7.71 (m, 14 H, Ar-H), 7.85 (s, 1H, Isoq-H); 13C NMR (75 MHz, CDCl3) δ 21.3, 28.2, 43.2, 56.0, 56.1, 90.5, 107.7, 110.6, 116.4, 117.8, 118.1, 119.0, 124.9, 126.1, 126.6, 127.0, 127.5, 127.7, 127.9, 128.4, 129.1, 129.4, 129.5, 129.6, 129.8, 132.5, 133.1, 138.4, 139.2, 139.3, 148.3, 150.3, 153.6, 181.5; MS (EI, 70 eV) m/z (%): 622 (M+, 100). Anal. Calcd. for C38H30N4O3S (622.74): C, 73.29; H, 4.86; N, 9.00; S, 5.15. Found: C, 73.20; H, 4.79; N, 9.08; S, 5.04.

8,9-Dimethoxy-3-(3-(3-(4-methoxyphenyl)-1-phenyl-1 H-pyrazol-4-yl)acryloyl)-2-(thiophen-2-yl)-5,6-dihydropyrrolo[2,1-a]isoquinoline-1-carbonitrile (18d):

Yellow crystals; DMF; yield (76%); mp 257–259 °C; 1H NMR (300 MHz, CDCl3) δ 3.05–3.09 (m, 2 H, CH2), 3.87 (s, 3 H, OCH3), 3.95 (s, 3 H, OCH3), 3.98 (s, 3 H, OCH3), 4.63–4.68 (m, 2 H, CH2), 6.54 (d, 1H, CH, J = 15.6 Hz), 6.79 (s, 1H, Isoq-H), 6.99 (d, 1H, CH, J = 8.7 Hz), 7.23–7.71 (m, 13H, Ar-H), 7.85 (s, 1H, Isoq-H); 13C NMR (75 MHz, CDCl3) δ 28.2, 43.2, 55.3, 55.9, 56.1, 90.5, 107.6, 110.6, 114.1, 116.4, 117.8, 118.0, 118.9, 124.5, 124.8, 126.1, 126.6, 127.0, 127.5, 127.7, 127.8, 129.5, 129.6, 129.7, 129.9, 132.5, 133.1, 139.2, 139.3, 148.3, 150.3, 153.3, 159.9, 181.4; MS (EI, 70 eV) m/z (%): 638 (M+, 100). Anal. Calcd. for C38H30N4O4S (638.74): C, 71.46; H, 4.73; N, 8.77; S, 5.02. Found: C, 71.52; H, 4.65; N, 8.66; S, 5.10.

Synthesis of 8,9-dimethoxy-2-(thiophen-2-yl)-3-(5-(p-tolyl)-4,5-dihydro-1 H-pyrazol-3-yl)-5,6-dihydropyrrolo[2,1-a]isoquinoline-1-carbonitrile (19).

A mixture of 8,9-dimethoxy-2-(thiophen-2-yl)-3-(3-(p-tolyl)acryloyl)-5,6-dihydropyrrolo[2,1-a]isoquinoline-1-carbonitrile 16f (0.48 g, 1 mmol) and hydrazine hydrate (0.21 mL, 1 mmol) in ethanol (10 mL) was refluxed for 30 min. The reaction mixture was cooled and the solid formed was collected, washed with ethanol and crystallized from acetonitrile to give the corresponding pyrazoline derivative 19. Orange crystals; yield (75%); mp 209–211 °C; IR (KBr) Inline graphic 3314 (NH), 2202 (CN) cm− 1; 1H NMR (300 MHz, CDCl3) δ 2.35 (s, 3 H, CH3), 2.58–2.67 (m, 1H, CH-Pyrazoline), 2.95–3.01 (m, 1H, CH-Pyrazoline), 3.02–3.07 (m, 2 H, CH2), 3.94 (s, 3 H, OCH3), 3.97 (s, 3 H, OCH3), 4.52–4.57 (m, 2 H, CH2), 4.69–4.75 (m, 1H, CH-Pyrazoline), 6.78 (s, 1H, Isoq-H), 6.99–7.35 (m, 7 H, Ar-H), 7.81 (s, 1H, Isoq-H), 9.49 (s, 1H, NH); 13C NMR(75 MHz, CDCl3) δ 20.9, 28.3, 42.6, 43.0, 55.8, 55.9, 63.5, 89.4, 107.0, 110.5, 117.0, 118.6, 121.4, 124.1, 125.3, 126.6, 127.0, 127.6, 128.1, 128.3, 129.2, 132.7, 137.3, 138.5, 143.9, 148.1, 149.3; MS (EI, 70 eV) m/z (%): 494 (M+, 100). Anal. Calcd. for C29H26N4O2S (494.61): C, 70.42; H, 5.30; N, 11.33; S, 6.48. Found: C, 70.35; H, 5.38; N, 11.22; S, 6.40.

Synthesis of 3-(1-cyano-8,9-dimethoxy-2-(thiophen-2-yl)-5,6-dihydropyrrolo[2,1-a]isoquinolin-3-yl)-N-phenyl-5-(p-tolyl)-4,5-dihydro-1 H-pyrazole-1-carbothioamide (20).

To a solution of 8,9-dimethoxy-2-(thiophen-2-yl)-3-(5-(p-tolyl)-4,5-dihydro-1H-pyrazol-3-yl)-5,6-dihydropyrrolo[2,1-a]isoquinoline-1-carbonitrile 19 (0.49 g, 1 mmol) in dry ether (10 mL), phenyl isothiocyanate (0.135 g, 1 mmol) was added. The reaction mixture was stirred for 5 h. The solid product separated was collected, washed with ethanol and crystallized from N,N-dimethylformamide to give compound 20. White crystals; yield (81%); mp 229–231 °C; IR (KBr) Inline graphic 3530 (NH), 2208 (CN) cm− 1; 1H NMR (300 MHz, CDCl3) δ 2.33 (s, 3 H, CH3), 2.67–2.74 (m, 1H, CH-Pyrazoline), 3.10–3.15 (m, 2 H, CH2), 3.41–3.51 (m, 1H, CH-Pyrazoline), 3.96 (s, 3 H, OCH3), 3.97 (s, 3 H, OCH3), 4.51–4.59 (m, 2 H, CH2), 5.94–5.99 (m, 1H, CH-Pyrazoline), 6.80 (s, 1H, Isoq-H), 7.00-7.63 (m, 12 H, Ar-H), 7.81 (s, 1H, Isoq-H), 9.00 (s, 1H, NH); 13C NMR (75 MHz, CDCl3) δ 21.0, 28.3, 43.4, 43.9, 56.0, 56.1, 62.2, 91.1, 107.4, 110.7, 116.2, 118.0, 120.0, 122.3, 124.1, 125.3, 125.4, 125.5, 127.3, 127.6, 128.5, 129.1, 129.3, 131.4, 137.2, 138.0, 138.5, 138.7, 147.7, 148.4, 150.1, 173.6; MS (EI, 70 eV) m/z (%): 629 (M+, 100). Anal. Calcd. for C36H31N5O2S2 (629.80): C, 68.66; H, 4.96; N, 11.12; S, 10.18. Found: C, 68.59; H, 4.87; N, 11.24; S, 10.10.

Synthesis of 3-(5-(p-tolyl)-4,5-dihydro-1 H-pyrazol-3-yl)-8,9-dimethoxy-2-(thiophen-2-yl)-5,6-dihydropyrrolo[2,1-a]isoquinoline-1-carbonitrile derivatives (21 and 22).

Reflux of 8,9-dimethoxy-2-(thiophen-2-yl)-3-(5-(p-tolyl)-4,5-dihydro-1H-pyrazol-3-yl)-5,6-dihydropyrrolo[2,1-a]isoquinoline-1-carbonitrile 19 (0.49 g, 1 mmol) in acetic anhydride or formic acid (10 mL) for 30 min and the mixture was cooled, diluted with water and the resulting solid product was collected and crystallized from ethanol to give compounds 21 and 22.

3-(1-Acetyl-5-(p-tolyl)-4,5-dihydro-1 H-pyrazol-3-yl)-8,9-dimethoxy-2-(thiophen-2-yl)-5,6-dihydropyrrolo[2,1-a]isoquinoline-1-carbonitrile (21):

Green crystals; yield (80%); mp 216–218 °C; IR (KBr) Inline graphic 2189 (CN), 1657 (CO) cm− 1; 1H NMR (300 MHz, CDCl3) δ 2.31 (s, 3 H, CH3), 2.37 (s, 3 H, COCH3), 2.64–2.72 (m, 1H, CH-Pyrazoline), 3.09–3.13 (m, 2 H, CH2), 3.26–3.35 (m, 1H, CH-Pyrazoline), 3.96 (s, 3 H, OCH3), 3.97 (s, 3 H, OCH3), 4.61–4.67 (m, 2 H, CH2), 5.32–5.35 (m, 1H, CH-Pyrazoline), 6.80 (s, 1H, Isoq-H), 7.01–7.38 (m, 7 H, Ar-H), 7.81 (s, 1H, Isoq-H); 13C NMR (75 MHz, CDCl3) δ 20.8, 21.8, 28.2, 43.3, 43.4, 55.8, 55.9, 58.5, 90.6, 107.1, 110.5, 116.3, 118.1, 122.8, 124.1, 125.3, 125.5, 127.0, 127.2, 129.0, 129.1, 131.7, 137.1, 137.9, 138.1, 146.5, 148.1, 149.8, 168.0; MS (EI, 70 eV) m/z (%): 536 (M+, 100). Anal. Calcd. for C31H28N4O3S (536.65): C, 69.38; H, 5.26; N, 10.44; S, 5.97. Found: C, 69.30; H, 5.19; N, 10.32; S, 5.90.

3-(1-Formyl-5-(p-tolyl)-4,5-dihydro-1 H-pyrazol-3-yl)-8,9-dimethoxy-2-(thiophen-2-yl)-5,6-dihydropyrrolo[2,1-a]isoquinoline-1-carbonitrile (22):

White crystals; yield (82%); mp 237–239 °C;; IR (KBr) Inline graphic 2195 (CN), 1659 (CO) cm− 1; 1H NMR (300 MHz, CDCl3) δ 2.32 (s, 3 H, CH3), 2.69–2.76 (m, 1H, CH-Pyrazoline), 3.09–3.13 (m, 2 H, CH2), 3.29–3.39 (m, 1H, CH-Pyrazoline), 3.96 (s, 3 H, OCH3), 3.97 (s, 3 H, OCH3), 4.64–4.67 (m, 2 H, CH2), 5.24–5.30 (m, 1H, CH-Pyrazoline), 6.81 (s, 1H, Isoq-H), 7.02–7.38 (m, 7 H, Ar-H), 7.81 (s, 1H, Isoq-H), 8.92 (s, 1H, CHO); 13C NMR (75 MHz, CDCl3) δ 20.9, 28.2, 43.6, 43.7, 55.9, 56.0, 57.7, 91.0, 107.3, 110.6, 116.3, 118.1, 122.5, 124.7, 125.6, 125.7, 127.2, 127.4, 129.2, 129.4, 131.7, 136.9, 137.6, 138.4, 148.3, 148.5, 150.0, 159.6; MS (EI, 70 eV) m/z (%): 522 (M+, 100). Anal. Calcd. for C30H26N4O3S (522.62): C, 68.95; H, 5.01; N, 10.72; S, 6.13. Found: C, 68.87; H, 5.08; N, 10.83; S, 6.06.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary Material 1 (5.7MB, docx)

Author contributions

“M. S. Mikhail” wrote the main manuscript text.“H. M. Hassaneen*and A. W. Erian*” supervision and reviewed the manuscript.“M. A. M. Teleb, M. G. Kamel, M. T. Helmy” supervision, methodology, conceptualisation, prepared schemes, figures, tables and reviewed the manuscript.

Funding

Open access funding provided by The Science, Technology & Innovation Funding Authority (STDF) in cooperation with The Egyptian Knowledge Bank (EKB).

Data availability

All data generated or analyzed during this study are included in this published article and its supplementary information file.

Declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Footnotes

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Contributor Information

Hamdi M. Hassaneen, Email: hhassaneen@sci.cu.edu.eg, Email: hamdi_251@yahoo.com

Ayman W. Erian, Email: erian11@hotmail.com

References

  • 1.Kostanecki S, Tambor J. Ber Dtsch Chem Ges. 1899;32:1921. [Google Scholar]
  • 2.Lemes SR, ESilva CR, Véras JH, Chen-Chen L, Lima RS, Perez CN. Montes de Sousa MA, de Melo PR, Da Silva junior N. J Drug Chem Toxicol. 2018;43:383. [DOI] [PubMed] [Google Scholar]
  • 3.Rupe H, Wasserzug D, Ber. Dtsch Chem Ges. 1901;34:3527. [Google Scholar]
  • 4.Shenvi S, Kumar K, Hatti KS, Rijesh K, Diwakar L, Reddy GC. Eur J Med Chem. 2013;62:435. [DOI] [PubMed] [Google Scholar]
  • 5.Mohamed MF, Mohamed MS, Shouman SA, Fathi MM, Abdelhamid IA. Appl Biochem Biotechnol. 2012;168:1153. [DOI] [PubMed] [Google Scholar]
  • 6.Mohamed MF, Mohamed MS, Fathi MM, Shouman SA, Abdelhamid IA. Anticancer Agents Med Chem. 2014;14:1282. [DOI] [PubMed] [Google Scholar]
  • 7.Sashidhara KV, Kumar A, Kumar M, Sarkar J, Sinha S. Bioorg Med Chem Lett. 2010;20:7205. [DOI] [PubMed] [Google Scholar]
  • 8.Helmy MT, Sroor FM, Mahrous KF, Mahmoud K, Hassaneen HM, Saleh FM, Abdelhamid IA, Teleb MAM. Arch Pharm (Weinheim). 2022: 355. [DOI] [PubMed]
  • 9.Asiri AM, Khan SA, Molecules. 2011; 16: 523. [DOI] [PMC free article] [PubMed]
  • 10.Lahtchev KL, Batovska DI, Parushev SP, Ubiyvovk VM, Sibirny AA. Eur J Med Chem. 2008;43:2220. [DOI] [PubMed] [Google Scholar]
  • 11.Hsieh HK, Tsao LT, Wang JP, Lin CN. J Pharm Pharmacol. 2000;52:163. [DOI] [PubMed] [Google Scholar]
  • 12.Bandgar BP, Gawande SS, Bodade RG, Gawande NM, Khobragade CN. Bioorg Med Chem. 2009;17:8168. [DOI] [PubMed] [Google Scholar]
  • 13.Bekhit AA, Abdel-Aziem T. Bioorg Med Chem. 2004;12:1935. [DOI] [PubMed] [Google Scholar]
  • 14.Onyilagha JC, Malhotra B, Elder M, French CJ, Towers GH. N Can J Plant Pathol. 1997;19:133. [Google Scholar]
  • 15.Li R, Kenyon GL, Cohen FE, Chen X, Gong B, Dominguez JN, Davidson E, Kurzban G, Miller RE, Nuzum EO, Rosenthal PJ, McKerrow JH. J Med Chem. 1995;38:5031. [DOI] [PubMed] [Google Scholar]
  • 16.Lin CN, Hsieh HK, Ko HH, Hsu MF, Lin HC, Chang YL, Chung MI, Kang JJ, Wang JP, Teng CM. Drug Dev Res. 2001;53:9. [Google Scholar]
  • 17.Heidari MR, Foroumadi A, Amirabadi A, Samzadeh-Kermani A, Azimzadeh BS, Eskandarizadeh A. Ann N Y Acad Sci. 2009;1171:399. [DOI] [PubMed] [Google Scholar]
  • 18.Eddarir S, Cotelle N, Bakkour Y, Rolando C. Tetrahedron Lett. 2003;44(28):5359. [Google Scholar]
  • 19.Bianco A, Cavarischia C, Farina A, Guiso M, Marra CA. Tetrahedron Lett. 2003;44(51):9107. [Google Scholar]
  • 20.Braun RU, Ansorge M, Mueller TJ. Chem Eur J. 2006;12(35):9081. [DOI] [PubMed] [Google Scholar]
  • 21.Takahashi S, Kuroyama Y, Sonogashira K, Hagihara N, Synthesis. 1980; 11(47): 627.
  • 22.Xu LW, Li L, Xia CG, Zhao PQ. Helv Chim Acta. 2004;87(12):3080. [Google Scholar]
  • 23.Kamakshi R, Reddy BSR. J Polym Sci. 2008;46(4):1521. [Google Scholar]
  • 24.Prakash O, Kumar A, Sadana A, Prakash R, Singh SP, Claramunt RM, Sanz D, Alkorta I, Elguero J, Tetrahedron. 2005; 61(27): 6642.
  • 25.Campos-Buzzi F, Campos JP, Tonini PP, Correa R, Yunes RA, Boeck P, Cechinel-Filho V. Arch Pharm Chem Life Sci. 2006;339(7):361. [DOI] [PubMed] [Google Scholar]
  • 26.Kozlowski D, Trouillas P, Calliste C, Marsal P, Lazzaroni R, Duroux JL. J Phys Chem. 2007;111(6):1138. [DOI] [PubMed] [Google Scholar]
  • 27.Nowakowska Z, Eur. J Med Chem. 2007;42(2):125. [DOI] [PubMed] [Google Scholar]
  • 28.Bentley KW. Nat Prod Rep. 2006;23(3):444. [DOI] [PubMed] [Google Scholar]
  • 29.Kitson RR, Millemaggi A, Taylor RJ. Angew Chem Int Ed Engl. 2009;48(50):9426. [DOI] [PubMed] [Google Scholar]
  • 30.Janecka A, Wyrebska A, Gach K, Fichna J, Janecki T. Drug Discov Today. 2012;17(11–12):561. [DOI] [PubMed] [Google Scholar]
  • 31.Houlihan WJ, Munder PG, Handley DA, Cheon SH, Parrino VA. J Med Chem. 1995;38:234. [DOI] [PubMed] [Google Scholar]
  • 32.Awasthi SK, Mishra N, Kumar B, Sharma M, Bhattacharya A, Mishra LC, Bhasin VK. Med Chem Res. 2009;18:407. [Google Scholar]
  • 33.Zhang XW, Zhao DH, Quan YC, Sun LP, Yin XM, Guan LP. Med Chem Res. 2010;19:403. [Google Scholar]
  • 34.Szliszka E, Czuba ZP, Mazur B, Sedek L, Paradysz A, Krol W. Int J Mol Sci. 2010;11:1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Ilango K, Valentina P, Saluja G. Res J Pharm Biol Chem Sci. 2010;1:354. [Google Scholar]
  • 36.Neves MP, Lima RT, Choosang K, Pakkong P, Nascimento MSJ, Vasconcelos H, Pinto M, Silva AMS, Cidade H. Chem Biodivers. 2012;9:1133. [DOI] [PubMed] [Google Scholar]
  • 37.Bag S, Ramar S, Degani MS. Med Chem Res. 2009;18:309. [Google Scholar]
  • 38.Lunardi F, Guzela M, Rodrigues AT, Corre R, Eger-Mangrich I, Steindel M, Grisard EC, Assreuy J, Calixto JB, Santos AR. S Antimicrob Agents Chemother. 2003;47:1449. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Yamali C, Sakagami H, Uesawa Y, Kurosaki K, Satoh K, Masuda Y, Yokose S, Ece A, Bua S, Angeli A, Supuran CT, Gul HI. Eur J Med Chem. 2021;217:113351. [DOI] [PubMed] [Google Scholar]
  • 40.Abu-Hashem AA. J Het Chem. 2021;58(3):805. [Google Scholar]
  • 41.Abu-Hashem AA, Al-Hussain SA. Pharmaceuticals. 2024;17(12):1632. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Lin Z, Ning X, Lai R, Hai L, Nie R, Guo L, Li G, Yang Z, Wu Y. Eur J Med Chem. 2024;279:116852. [DOI] [PubMed] [Google Scholar]
  • 43.Fischer F, Matthisson M, Herrling PL. Neurodegener Dis. 2004;1(1):50. [DOI] [PubMed] [Google Scholar]
  • 44.Bhardwaj V, Gumber D, Abbot V, Dhiman S, Sharma P, Rsc. Adv. 2015;5(20):15233. [Google Scholar]
  • 45.Roberts MF, Zenk MH, Springer, Berlin., Duozhi S, Meng C, Lijia L, Qingqing W, Shuangyue L, Lingzhi W, Rufeng WJ, Ethnopharmacol H, Yu S, Rong Q, Likun W, Zhibo Z, Weikang H, Xirui F, Ying Y, Hui W. Eur. J. Gastroenterol. Hepatol. 2023; 35: 854; d), Kumar AL, Priyanka G, Prateek P, Neelima G. Struct. Chem. 2023; 34: 837.
  • 46.Loidl G, Polossek T, Mannschreck A, von Angerer EJ, Med. Chem., 1997; 40: 3524–3533; b) Kraus GA, Gupta V, Kohutb M, Singh N. Bioorg. Med. Chem. Lett., 2009; 19: 5539. [DOI] [PubMed]
  • 47.Kamel MG, Sroor FM, Othman AM, Mahrous KF, Saleh FM, Hassaneen HM, Abdallah TA, Abdelhamid IA, Teleb MAM. Monatsh Chem. 2022;153:211. [Google Scholar]
  • 48.Mohamed Teleb MA, Hassaneen HM, Abdelhamid IA, Saleh FM. J Heterocycl Chem. 2024;61(2):336. [Google Scholar]
  • 49.Laboud YN, Hassaneen HM, Hassaneen HME, Mohamed Teleb MA, Saleh FM. J Heterocycl Chem. 2023;60(9):1565. [Google Scholar]
  • 50.Laboud YN, Hassan N, Hassaneen HM, Hassaneen HME, Saleh FM, Mohamed Teleb MA. Anticancer Agents Med Chem. 2023;23:1192. [DOI] [PubMed] [Google Scholar]
  • 51.Teleb MAM, Hassaneen HM, Abdelhadi HA, Laboud YN, Saleh FM. Heterocycles. 2021;102:1729. [Google Scholar]
  • 52.Leonard NJ, Boyer JH. J Am Chem Soc. 1950;72(7):2980. [Google Scholar]
  • 53.Openshaw HTT, Whittaker NJ. Chem Soc. 1960;42(0):4939. [Google Scholar]
  • 54.Eweiss NF, Osman AJ. Heterocycl Chem. 1980;17:1713. [Google Scholar]
  • 55.Shawali AS, Abdelhamid AO. Bull Chem Soc Jpn. 1976;49:321. [Google Scholar]
  • 56.Farag AM, Algharib MS, Org. Prep Proced Int. 1988;20:521. [Google Scholar]
  • 57.Hassaneen HM, Shawali AS, Elwan NM, Abounada NM. Sulfur Lett. 1992;13:273. [Google Scholar]
  • 58.Kapadiya KM, Kavadia KM, Manvar PA, Ranjan K, Kavadia KM, Manvar PA, Khunt RC. Anti-Infective Agents. 2002;13:138. [Google Scholar]
  • 59.Mosmann TJ. Immunol Methods. 1983;65:55. [DOI] [PubMed] [Google Scholar]
  • 60.Thabrew MI, Hughes RD, McFarlance IG. J Pharm Pharmacol. 1997;49:1132–5. [DOI] [PubMed] [Google Scholar]
  • 61.El-Menshawi BS, Fayad W, Mahmoud K, El-Hallouty SM, El-Manawaty M, Olofsson MH, Linder S. Indian J Exp Biol. 2010;48:258. [PubMed] [Google Scholar]
  • 62.Sroor FM, Othman AM, Aboelenin MM, Mahrous KF. Med Chem Res, 202; 31: 400.
  • 63.Jordao AK, Novais J, Leal B, Escobar AC, dos Santos Júnior HM, Castro HC, Ferreira VF. Eur J Med Chem. 2013;63:196. [DOI] [PubMed] [Google Scholar]
  • 64.Suresh N, Nagesh HN, Renuka J, Rajput V, Sharma R, Khan IA, Gowri CSKV. Eur J Med Chem. 2014;71:324. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supplementary Material 1 (5.7MB, docx)

Data Availability Statement

All data generated or analyzed during this study are included in this published article and its supplementary information file.

Articles from BMC Chemistry are provided here courtesy of BMC

RESOURCES